Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for malignant peritoneal mesothelioma (MPM)

Taub, Robert N.; Hesdorffer, Mary; Keohan, Mary Louise; Chabot, John A.; Fountain, Karen S.; Talbot, Susan; Gabay, Michelle; Lee, S.

doi:10.1200/jco.2005.23.16_suppl.7175

JCO

2005

DOI: 10.1200/jco.2005.23.16_suppl.7175

|View full text |Cite

Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for malignant peritoneal mesothelioma (MPM)

Robert N. Taub

Mary Hesdorffer

Mary Louise Keohan

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2007

2022

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug used by Loggie was mitomycin C [2]. Numerous single institution reports support the proposal that a complete or near complete cytoreductive surgery followed by HIPEC improved survival [3][4][5][6][7][8][9][10][11]. A multiinstitutional data registry of 405 patients was performed by Yan and coworkers [12] and a systematic review and metaanalysis by Helm and coworkers [13] further supported that cytoreductive surgery plus HIPEC achieved prolonged survival.…”

mentioning

confidence: 99%

Long-term Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma

2022

Journal of Clinical Haematology

View full text Add to dashboard Cite

are credited. chemotherapy (HIPEC). The drug used by Loggie was mitomycin C [2]. Numerous single institution reports support the proposal that a complete or near complete cytoreductive surgery followed by HIPEC improved survival [3][4][5][6][7][8][9][10][11]. A multiinstitutional data registry of 405 patients was performed by Yan and coworkers [12] and a systematic review and metaanalysis by Helm and coworkers [13] further supported that cytoreductive surgery plus HIPEC achieved prolonged survival. This combined treatment was presented as a standard of care in 2016 [14]. Recently, Kusamura et al. published practice guidelines from an extensive literature review. Kusamura et al. concluded that median survival has increased from one year

show abstract

mentioning

confidence: 99%

Long-term Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma

2022

Journal of Clinical Haematology

View full text Add to dashboard Cite

show abstract

Advances in diffuse malignant peritoneal mesothelioma

Yan

Hassan

Welch³

et al. 2007

Oncol Rev

View full text Add to dashboard Cite

Malignant mesothelioma is a highly aggressive neoplasm. The incidence of malignant mesothelioma is increasing worldwide. Diffuse malignant peritoneal mesothelioma (DMPM) represents one-fourth of all mesotheliomas. Association of asbestos exposure with DMPM has been observed, especially in males. A great majority of patients present with abdominal pain and distension, caused by accumulation of tumors and ascitic fluid. In the past, DMPM was considered a pre-terminal condition; therefore attracted little attention. Patients invariably died from their disease within a year. Recently, several prospective trials have demonstrated median survival of 40 to 90 months and 5-year survival of 30% to 60% after the combined treatment using cytoreductive surgery and perioperative intraperitoneal chemotherapy. This improvement in survival has prompted new searches into the medical science related to DMPM, a disease previously ignored as uninteresting. This review article focuses on the key advances in the epidemiology, diagnosis, staging, treatments and prognosis of DMPM that have occurred in the past decade.

show abstract

Local-regional approach to diffuse malignant peritoneal mesothelioma

Sugarbaker¹

2007

Gastroentérologie Clinique et Biologique

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for malignant peritoneal mesothelioma (MPM)

Cited by 5 publications

References 0 publications

Long-term Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma

Long-term Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma

Advances in diffuse malignant peritoneal mesothelioma

Local-regional approach to diffuse malignant peritoneal mesothelioma

Contact Info

Product

Resources

About